TOPLINE:

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses.

METHODOLOGY:

GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence supporting its effectiveness is lacking.

Researchers used a combination of real-world case reports and mathematical modeling to examine the efficacy of a less frequent dosing of GLP-1 RAs for weight maintenance.

They analyzed the data of two patients who used GLP-1 RAs at less frequent dosing schedules than recommended; patient 1 with obesity and prediabetes self-administered 7.5 mg tirz

See Full Page